BrainsWay Ltd. (NASDAQ:BWAY) Q1 2022 Earnings Conference Call May 11, 2022 8:30 AM ET
Company Participants
Bob Yedid – LifeSci Advisors
Chris von Jako – President and Chief Executive Officer
Scott Areglado – Chief Financial Officer
Conference Call Participants
Jeffery Cohen – Ladenburg Thalmann
Jayson Bedford – Raymond James
Steven Lichtman – Oppenheimer
Jason Wittes – Loop Capital
Carl Byrnes – Northland Capital Markets
Operator
Greetings, and welcome to BrainsWay First Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.
It is now my pleasure to introduce your host, Bob Yedid with LifeSci Advisors. Thank you. You may begin.
Bob Yedid
Thank you, Doug, and thank you all. And welcome to BrainsWay’s first quarter 2022 earnings conference call. With us today are BrainsWay’s President and Chief Executive Officer, Chris von Jako; and Chief Financial Officer, Scott Areglado. The format for today’s call will be a discussion of recent trends and business updates from Chris, followed by a detailed discussion of the financials from Scott. Then we will open up your call – then we open up the call for your questions. Earlier today, BrainsWay released financial results for the three months March 31, 2022. The copy of the press release is available on the company’s Investor Relations website.
Before I turn the call over to Chris and Scott, I’d like to remind you that this conference call, including both management’s prepared remarks and the question-and-answer session may contain projections or other forward-looking statements regarding among other topics, BrainsWay’s anticipated future operating and financial performance, business plans and prospects and expectations for its products and pipeline, which are all subject to risk and uncertainties, including shifting market conditions, resulting from the COVID-19 pandemic, the global supply chain crisis, as well as the use of non-GAAP financial information.
Additional information regarding these and other risks are available in the company’s earnings release and its other filings with the Securities and Exchange Commission, including the risk factors section contained in BrainsWay’s Form 20-F.
With those prepared remarks, it’s my pleasure to turn the call over to Chris von Jako, CEO. Chris?
Chris von Jako
Thank you, Bob. Welcome, everyone, and thank you for joining us today. To begin, our business continues to perform extremely well while the Omicron variant had a slight impact early in the first quarter, demand for our therapy in multiple indication continues to remain steady. Importantly, we expect that our current positive operating trends that are driving our strong growth in recent quarters highlighted by our latest achievements on commercial, clinical, regulatory and reimbursement fronts will lead to further growth for BrainsWay throughout 2022 and beyond.